Right, Pipedream, well said indeed. There is a very close parallel with the previous sharp fall that took the price down to 11 cents. What counts is not the current level of the share price, but its direction in the short, medium and long term.
Actually investors should be concerned where the price is as any cash raise (dilution) hinges on the stock price and valuation. They need to raise $1.5M otherwise Rapimeds will not be manufactured and distributed: